Aldeyra Therapeutics initiates trials of ADX-629 for Covid-19,

The Phase II trials come after successful Phase I clinical trial of ADX-629, which showed no treatment-related adverse events at tested doses and target …, The Phase II trials come after successful Phase I clinical trial of ADX-629, which showed no treatment-related adverse events at tested doses and target …, Read More

Scroll to Top